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Abstract: Aim of this study was to investigate the relationship
between height in young adult age and Parkinson’s disease
(PD) risk. We included 266 persons affected by idiopathic PD.
Patients were matched by age and sex to 266 controls by a
random selection from the municipality of residence. We col-
lected information about height preceding PD from ofﬁcial
documents where these characteristics referred to young adult
age (nearly 30 years). We compared height in cases and con-
trols by calculating differences in mean distribution and by 2
analyses. Crude and adjusted odds ratios (OR) and 95% con-
ﬁdence intervals (CI) were calculated by logistic regression
models. Mean height was signiﬁcantly lower in persons af-
fected by PD compared to controls (P  0.03). Difference was
signiﬁcant only in men (P 0.001). Logistic regression models
showed an inverse association between height and PD (OR
0.35; CI 0.16, 0.79; P  0.01 comparing individuals in the
highest percentiles of height with those in the lowest). Our
results indicate an association between height and PD in men.
Considering that dopamine sensitivity in the hypothalamic-
pituitary axis is related to adult height, our ﬁndings suggest a
relationship between PD and factors modulating somatic
growth early in life. © 2007 Movement Disorder Society
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In medical literature, stature has been associated with
diseases including cancer and cardiovascular disor-
ders.1–3 The accumulating evidence that stature is an
indicator of phenomena occurring during body growth
linked to pathological processes implies that the search
for risk factors associated with diseases occurring at a
late age should be extended to the early phases of life.4
Growth hormone (GH) release after L-dopa stimula-
tion is reduced in children with short stature.3 A func-
tional relationship between striatal extracellular soma-
tostatin and the GH and dopamine (DA) systems in the
striatum of anesthetized rats has been reported.5 Also,
dopamine receptor genes contribute to the inheritability
of stature, and a possible haplotypic association between
stature and the DRD2 gene has been reported as well.6,7
These data suggest an interaction between hypothalamic-
pituitary axis activity and tissue sensitivity to dopami-
nergic stimulation. If this is true, people who later de-
velop Parkinson’s disease (PD) may have characteristics
related to a lower sensitivity to dopaminergic stimula-
tion, preceding clinical symptoms.
We conducted a case-control study to investigate the
possible association between PD and height in ages prior
to the clinical onset of the disease.
PATIENTS AND METHODS
Cases and Controls
Patients with idiopathic PD were consecutively re-
cruited among outpatients from the neurological clinics
of Palermo and Messina, Italy, starting February 2001 to
May 2005. The same diagnostic criteria used in a popu-
lation-based survey on the prevalence of PD in Sicily
were applied.8,9 Diagnoses of idiopathic PD were
reached in two phases. In the ﬁrst phase, parkinsonism
was identiﬁed by the presence of at least two of four
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cardinal signs in people who were not on anti-parkinso-
nian therapy: tremor at rest, rigidity, bradykinesia, and
impaired postural reﬂexes; at least one of the above signs
was required in individuals who were taking anti-parkinso-
nian therapy. In the second phase, diagnoses of idiopathic
PD were supported by unilateral onset, progressive course,
asymmetry of signs, and good responsiveness to anti-par-
kinsonian drugs (L-dopa or dopamine agonists). We con-
sidered as good responsiveness an improvement of at least
30% in the UPDRS motor scores compared to the score
obtained before treatment. Vascular and other forms of
parkinsonism were excluded through a screening for
history of stroke, head trauma, encephalitis, and sudden
onset or stepwise progression of symptoms. We also
excluded individuals who consumed neuroleptic drugs
during the 6 months before the onset of symptoms, or
who showed the presence of cognitive impairment or of
other neurological signs within the ﬁrst year of the onset
of symptoms. Brain CT, MRI, and SPECT, though not
critical for inclusion, were also evaluated when avail-
able. PD onset was deﬁned as the year in which one of
the cardinal signs was ﬁrst noted.
PD patients were matched (1:1) by sex and age (2
years) to individuals free of neurological diseases ran-
domly selected from the population records of the mu-
nicipality of residence of the case. Diagnoses were re-
viewed by at least two neurologists. The same
neurologists, through an extensive review of medical
history and a careful neurological examination, ascer-
tained the absence of neurological diseases in controls.
We selected more than one control for each patient.
Whenever it was not possible to trace a control through
the information collected at the municipality records, or
the control refused to participate in the study, we inter-
viewed the next person in the randomization list.
Risk Factor Assessment
Height of cases and controls was abstracted from
ofﬁcial documents (passport, identity cards, other kind of
sources used in Italy such as association cards or rail-
ways cards where height is stated) where these charac-
teristics referred to young adult age (30 years). Clinical
records were also used when available. Trained person-
nel administered a face-to-face structured questionnaire
to each case or control before any decision regarding
diagnosis and inclusion was made. Clinical examination
of cases and controls were made by expert neurologists
trained in movement disorders.
Data Analysis
Differences between means of height in cases and
controls were compared by the t-test. Frequency distri-
bution of height was compared in cases and controls by
2 analysis. We estimated the association between height
and PD by the calculation of the odds ratio (OR). OR
with 95% conﬁdence intervals (CI) and two-tailed P
values (  0.05), adjusted for age, sex, education level,
type of work, smoking habits, and coffee consumption,
were calculated by logistic regression analyses. Logistic
models are ordinary models; for this reason a noncom-
plete correspondence may exists between the number of
cases and controls stratiﬁed by sex reported in the tables.
Height was categorized according to the percentiles of
distribution in the whole sample (25th, 50th, and 75th
percentiles) and independently for men and women. Sub-
jects were classiﬁed also as nonsmokers (less than an
average of a pack of cigarettes per month during adult
life) and smokers (at least an average of a pack of
cigarettes per month during adult life). Coffee consump-
tion was classiﬁed as nondrinkers (less than an average
of a cup of coffee per week during adult life) versus
drinkers (at least an average of a cup of coffee per week
during adult life). To calculate these habits, people were
also asked at what age they started smoking, or drinking
coffee, their age at cessation, and any possible discon-
tinuation. Education level, taken as completed years of
school, was stratiﬁed in 4 groups: 0 years, 1 to 8 years,
9 to 13 years, more than 13 years. The type of work was
divided in the following categories: intellectual, manual
workers, housewives, all others. Apart from the type of
work, other variables including age of cases and controls
were included in multivariate models as continuous or-
dinal variables. The local ethical committee revised and
approved the study.
RESULTS
Two hundred sixty-six cases and an equal number of
controls were included. Response rates were high both in
cases (90%) and in controls (86%), whose characteristics
are shown in Table 1. The distribution of the occupation
was not signiﬁcantly different among cases and controls,
although intellectual jobs were more represented in men
(both cases and controls). As previously reported in other
studies smokers were more common in controls com-
pared to cases but difference was not signiﬁcantly dif-
ferent. Coffee drinking was signiﬁcantly more frequent
among controls compared to cases. We observed no
differences in age distribution between cases and con-
trols. Mean age at PD onset and duration of PD symp-
toms at the date of interview were similar in men and
women. As shown in the table, mean difference of height
between cases and controls was about 1.4 cm, the median
difference being 1 cm (P  0.026). Mean height differ-
ence between cases and controls in men was 2.55 cm, the
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median difference being 2 cm (P  0.004). Both of the
observed extremes of height ranges were higher in
healthy men than in PD patients. Mean difference of
height between cases and controls in women was not
signiﬁcantly different (0.32 cm; P  0.58).
Table 2 illustrates calculations stratiﬁed by sex ac-
cording to the percentiles of height distribution. PD was
inversely associated with height (Table 2). This associ-
ation was signiﬁcant in men in the highest percentile,
with a signiﬁcant trend (P  0.01). We did not observe
any signiﬁcant association between PD and height
among women. Table 3 shows the results of multivariate
regression model where height of PD patients is com-
pared to the height of controls by stratifying for the
percentile of distribution of height within gender. The
lowest percentile for each gender represent the referent
category (lower than 165 cm in men and lower than 156
cm in women), the second category is between 165 and
173 in men and between 156 and 163 in women. Finally,
the highest percentile is higher than 173 cm in men and
higher than 163 in women. We also introduced a term for
interaction by gender and height. The interaction approx-
imated only the statistical signiﬁcance for the highest
percentile. This may be due to a sample not large enough
to discriminate the effect of gender, but it would anyway
suggest that the association between PD and height may
be different in men and women.
DISCUSSION
The results of the current study are consistent with an
inverse association between PD and height. The associ-
ation was extremely signiﬁcant among people in the
highest quartiles of height and in men. We did not ﬁnd,
on the contrary, an association between PD and height
among women.
Consideration on Methods
Our study has its strengths and its limits. The sample
size was large enough to allow a power of more than
TABLE 1. Characteristics of PD patients and controls
enrolled in the study
Cases Controls
Mean Median Range Mean Median Range
Age at interview
Both sexes 67.4 68.7 33–89 67.4 67.7 33–89
Men 67.3 68.6 34–89 67.0 67.0 37–89
Women 67.5 69.0 33–88 67.8 68.0 33–86
Age at PD onset
Both sexes 60.3 61.0 24–88 – – –
Men 60.7 61.5 24–88 – – –
Women 60.0 61.0 33–87 – – –
PD duration
Both sexes 6.0 5.0 1–20 – – –
Men 5.8 5.0 1–20 – – –
Women 6.2 5.0 1–16 – – –
Yrs of education
Both sexes 7.4 5.0 1–23 7.8 5.0 1–23
Men 7.7 5.0 1–23 8.8 8.0 1–23
Women 7.2 5.0 1.17 7.0 5.0 1–19
Height
Men 167.63a 168.0 147–180 170.18a 170.0 155–185
Women 159.72 160.0 147–175 160.04 160.0 145–178
aDifference between these means are calculated by t-test; all values
are two-sided. P  0.001.
TABLE 2. Height and PD: Frequency distribution and OR by univariate analysis
Cases (%) Controls (%) OR 95% CI P
Total 266 266
160 (Height 1) 60 (22.6) 63 (23.7) 1.00 (ref.) –
160–169 (Height 2) 156 (58.7) 92 (45.9) 1.78 1.12–2.82 0.01
169 (Height 3) 50 (18.8) 81 (30.5) 0.65 0.38–1.10 0.11
Men 123 122
165 (Height 1) 29 (23.6) 18 (14.8) 1.00 –
165–173 (Height 2) 73 (59.4) 67 (54.9) 1.48 0.72–3.07 0.30
173 (Height 3) 21 (17.0) 37 (30.3) 0.35 0.15–0.84 0.01
Women 143 144
156 (Height 1) 32 (20.8) 30 (20.8) 1.00 –
156–163 (Height 2) 74 (51.8) 76 (52.8) 0.91 0.48–1.72 0.9
163 (Height 3) 37 (25.9) 38 (26.4) 0.91 0.44–1.89 0.9
TABLE 3. Logistic regression analyses of height among
cases and controls
Variable OR 95% CI P
Height 1 1.00 (ref.) – –
Height 2 0.70 0.35–1.38 0.30
Height 3 0.35 0.16–0.79 0.01
Gender  height 2 1.33 0.53–3.29 0.54
Gender  height 3 2.72 0.94–7.83 0.063
OR adjusted by sex, age, yrs of education, type of work, smoking,
and coffee consumption.
Patients are classiﬁed by height1 height2 and height3 with respect to
the ﬁrst (Q1) and the third quartile (Q3) of each gender. People under
Q1 (male  165 cm; female  156) are in the ﬁrst category, while
people between Q1 and Q3 (male  173 cm; female  163) in the
second and, ﬁnally, people over Q3 in the last category.
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80% with CI of 95% and two-sided P values. Power
calculation was made considering a height difference of
at least 1 cm to detect an OR of 2. Power was estimated
for the whole sample; the differences observed in height
among women do not allow enough power to be sure that
the observed negative results are not due to chance alone.
This is demonstrated by the height gender interaction,
which approximates the statistical signiﬁcance. Diag-
noses were made independently of risk factor collection.
The diagnosis of idiopathic PD, based on validated cri-
teria suitable for epidemiological purposes, was reached
by at least two neurologists trained in movement disor-
ders who were not the same as those who administered
the questionnaire. The demographic characteristics of
cases and controls were similar. Strata by gender also
showed similar distributions. To reduce the risk of con-
founding and cohort effects, we performed analyses ad-
justed by sex, age, education, and type of work. We also
made adjustments for smoking and coffee consumption
because these risk factors have been reported to be as-
sociated either with both PD and somatic growth in many
studies and they could therefore represent potential con-
founders. This study has also its limits. The most evident
limit is the effort to retrospectively collect information
about height at ages many years before the onset of
disease symptoms. Information was collected from indi-
viduals and its accuracy was tested by reviewing ofﬁcial
documents such as identity cards, passports, or other
sources reporting such information, and by clinical
records when available. All people included in the study
were able to provide at least the identity card to collect
information on height. Potential errors caused by the
documents’ lack of accuracy would, however, be ran-
domly distributed throughout the whole sample.
Another limit derives from the inclusion of prevalent
cases. The large sample size, the disparity of results
between men and women, and particularly the increasing
signiﬁcant trend with increasing height reduce the risk of
prevalence–incidence bias but do not rule out this pos-
sibility altogether. The possibility exists in fact, that if
taller persons are at higher risk for other disease and with
a worst prognosis, then shorter individuals could be over
represented among PD patients. Finally, misdiagnoses
especially between idiopathic PD and vascular PD have
a very low chance to modify our results because of the
diagnostic criteria adopted. Moreover, in almost all the
patients enrolled in the study at least an imaging study
was performed.
Consideration on Results
This is to our knowledge the ﬁrst study exploring the
association between PD and height. The difference in
heights was signiﬁcant only for men. Interestingly, our
results did not reveal any association between PD and
height in women. If we look for a possible biological
explanation, the effect of estrogens has to be considered.
Many reports indicate that estrogen treatment tends to
reduce the ﬁnal adult height of tall girls.10 Other reports
have suggested an association between PD and the es-
trogen stimulation during a woman’s life.11–13 The inter-
action between sex steroid exposure and PD may partly
account for the lack of association we observed between
PD and height in women.
Many studies have been conducted investigating the
association between PD and other somatic characteristics
such as the body mass index (BMI) preceding disease
onset, but the results have been inconsistent.14,15 There
are several reasons for the discordant ﬁndings. Recall
and classiﬁcation bias presumably affected retrospective
studies in which the information was based only on
self-reported data. This is not anyway the case of the
study we refer to.14,15 Also, in diseases like PD, the
degenerative process starts many years before the onset
of symptoms and it is hard even in prospective studies to
discriminate the temporal relationship between continu-
ous phenomenon related to the exposure and the disease.
An ever increasing amount of data indicate the need to
explore factors occurring early in life, related to body
growth and tissue differentiation, which predetermine the
risk for chronic and degenerative diseases.1,2,4 For these
reasons we investigated the association between PD and
stature. There are several indications that corroborate our
ﬁndings. First, height is determined in the very early
phases of life and is only in part modiﬁed by other factors
possibly associated with PD. Second, it is possible to
collect information about height with sufﬁcient reliabil-
ity by retrieving clinical records or ofﬁcial documents
where such data are recorded before any disease has
occurred. Third, the temporal relationship between ﬁnal
adult height and the disease is clear and distinguishable.
Fourth, body growth expresses phenomena which are
clearly and closely linked to brain development. Recent
studies hypothesize that the pathological mechanisms
underlying PD follow steps that may be in some way
related to central nervous system development.16
Other interesting speculations increase the interest of a
possible relationship between PD and stature. Physical
symptoms, indicating a growth hormone deﬁciency, in-
clude reduced vitality, premature fatigue, reduced
strength, and a low tolerance to exercise. Individuals also
experience decreased psychological well-being, socially
inhibited behavior, low self-esteem, and emotional dis-
tress.17–19 Moreover, growth retardation seems to be as-
sociated with altered behavior and fear of novelty.19
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Many studies have suggested that a pre-morbid person-
ality may explain the inverse relationship observed be-
tween PD risk and some habits such as cigarette smok-
ing, coffee consumption, or alcohol drinking.20–22
According to this hypothesis, people who later develop
PD tend to avoid novelty seeking because of a person-
ality trait preexisting to PD. These results, considered
altogether, indicate that personality traits may simply
reﬂect an altered response to physiological and psycho-
logical stressors because of mechanisms associated with
growth retardation.
Previous studies have reported an inverse association
between stature and diseases like cardiovascular pathol-
ogies while a direct association has been reported be-
tween cancer and greater height.1,2,23 These studies pro-
vide no reason for believing that a selective morbidity or
mortality cohort effect may have generated our results.
A recent study also indicated an inverse association
between dementia and height,24 and it is increasingly
thought that certain events—-apart from genetic consid-
erations—-occurring in the initial phases of life make a
substantial contribution to what will ﬁnally happen with
ageing.
Height in adult life is inﬂuenced by many factors
operating early in life. The Intrauterine environment is
also important for body growth.23 The relationship be-
tween a degenerative disease like PD and events occur-
ring early in life strikes us as being an interesting issue
worth investigating through other epidemiological and
biological studies.
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